- Home
- OPK vs CRGX Comparison
OPK vs CRGX Comparison
Compare OPK & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPK
- CRGX
- Stock Information
- Founded
- OPK 2007
- CRGX 2021
- Country
- OPK United States
- CRGX United States
- Employees
- OPK N/A
- CRGX N/A
- Industry
- OPK Biotechnology: Pharmaceutical Preparations
- CRGX
- Sector
- OPK Health Care
- CRGX
- Exchange
- OPK Nasdaq
- CRGX Nasdaq
- Market Cap
- OPK N/A
- CRGX 190.0M
- IPO Year
- OPK 1995
- CRGX 2023
- Fundamental
- Price
- OPK $1.36
- CRGX $4.46
- Analyst Decision
- OPK Buy
- CRGX Hold
- Analyst Count
- OPK 4
- CRGX 7
- Target Price
- OPK $2.75
- CRGX $4.67
- AVG Volume (30 Days)
- OPK 3.5M
- CRGX 502.9K
- Earning Date
- OPK 08-06-2025
- CRGX 08-11-2025
- Dividend Yield
- OPK N/A
- CRGX N/A
- EPS Growth
- OPK N/A
- CRGX N/A
- EPS
- OPK N/A
- CRGX N/A
- Revenue
- OPK $689,408,000.00
- CRGX N/A
- Revenue This Year
- OPK N/A
- CRGX $57.81
- Revenue Next Year
- OPK $7.80
- CRGX N/A
- P/E Ratio
- OPK N/A
- CRGX N/A
- Revenue Growth
- OPK N/A
- CRGX N/A
- 52 Week Low
- OPK $1.19
- CRGX $3.00
- 52 Week High
- OPK $2.04
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- OPK 56.84
- CRGX 57.89
- Support Level
- OPK $1.26
- CRGX $4.09
- Resistance Level
- OPK $1.36
- CRGX $4.51
- Average True Range (ATR)
- OPK 0.04
- CRGX 0.18
- MACD
- OPK 0.01
- CRGX 0.00
- Stochastic Oscillator
- OPK 92.31
- CRGX 77.18
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.